Showing posts with label Breast-Cancer. Show all posts
Showing posts with label Breast-Cancer. Show all posts

Thursday, August 07, 2008

Could Where I Live Raise My Risk of Breast Cancer?

By Anne Krueger

My fellow blogger Sean Kelley recently wrote about how fat his home state is. (He lives in Alabama, second fattest state in the nation, according to stats from the Centers for Disease Control and Prevention.) One of Sean’s points was that it’s no surprise that fat Alabama also has a high incidence of diabetes. There is a proven obesity-diabetes link.

That got me thinking about a disease that weighs more heavily on my mind. Could where I live (Tennessee) affect my risk of getting breast cancer? And how does a person figure out how healthy her state is, anyway? Read More


Balancing Your Hormones Without Drugs... You Can Feel Good Again

Balancing Your Hormones Without Drugs... You Can Feel Good Again

$19.95
[ learn more ]

Add to Cart

Hormone imbalance can be reversed! Look and feel better than ever, just take the time to learn about yourself and read the information contained in this just released e-book about reversing hormone imbalance. Are you ready to finally look and feel great? If so... read on... - E-Book Version.(BH)

Thursday, July 17, 2008

No Evidence Breast Self-Exams Cut Cancer Deaths

(HealthDay News) -- Updated findings from an analysis of existing research continue to suggest that the oft-touted monthly breast self-exam may actually do more harm than good.

There is no evidence that the practice actually decreases deaths from breast cancer while it may actually double the number of unnecessary biopsies in women who do the exam compared with women who don't.

"At present, screening by breast self-examination or physical examination [by a trained health worker] cannot be recommended," two of the study authors, Jan Peter Kosters and Peter Gotzsche of the Nordic Cochrane Centre, stated in the review.

The current review, published in the most recent issue of The Cochrane Library, updates and corroborates information from a 2003 review of studies.

The American Cancer Society revised its guidelines five years ago based on emerging evidence and no longer recommends monthly breast self-exams. The monthly exam is now considered "an option" for women starting in their 20s.

The current review included two studies of almost 400,000 women in Russia and China. Women who did self-exams had 3,406 biopsies compared with only 1,856 biopsies in the group that did not do the exams. Differences in biopsy rates did not translate into differences in breast cancer mortality.

The China study found that rates of mastectomy and lumpectomy (or "breast-conserving" surgery) were similar regardless of whether women were doing self-exams or not.

As always, however, women who detect any change in their breast need to consult a doctor.

More information
Visit the National Cancer Institute for more on breast cancer.

Friday, February 29, 2008

Heart Hormones Beat Back Cancers in Mice

(HealthDay News) -- New research offers early evidence that hormones produced by the heart to control both blood pressure and volume could be harnessed to treat -- and possibly cure -- a wide range of cancers.

Following a month of intravenous treatment with any of four human cardiac peptide hormones, mice engineered to develop human pancreatic and breast cancer experienced dramatic results:

On average, 54 percent of those with breast cancer and 37 percent of those with pancreatic cancer were cured, without tumor recurrence or treatment side effects.

Even tumor shrinkage among non-cured mice was striking, with size reductions of 90-plus percent. And a more detailed analysis, hormone-by-hormone, revealed even stronger anti-cancer properties among certain hormones. In such best-case scenarios, the most effective hormones provoked full tumor elimination -- without surgery, chemotherapy or any other additional treatment -- in two-thirds of the mice with breast cancer and 80 percent of the mice with pancreatic cancer.

"This raises hope for turning cancer -- even when not fully cured -- into a chronic disease," said study author Dr. David L. Vesely, director of the department of molecular pharmacology and physiology at the University of South Florida's Cardiac Hormone Center, in Tampa.

Vesely is scheduled to present his findings April 9 at the Experimental Biology annual conference in San Diego. The findings were originally published in the journal in vivo last year.

"For 350 years, the heart has been thought of simply as a pump," Vesely said. "But we now know it makes hormones that lower your blood pressure and get rid of salt and water. So, first we took four of them that all come from the same gene, and looked at them in laboratory cell cultures, and found that they essentially eliminated 97 percent of exposed cancer cells within 24 hours."

With funding largely from the U.S. Veteran's Administration, the research team then grew human cancer cells in 1-month-old male and female mice, focusing first on pancreatic cancer, which Vesely described as the "worst of all," given the fast pace of its development, its poor treatment track record, and a mean survival rate of just four months.

Nearly 34,000 Americans are diagnosed with pancreatic cancer each year, and 32,000 die of the disease annually.

Some of the pancreatic cancer mice received a saline solution, while others were exposed to a month-long regimen of one of four cardiac hormones: long acting natriuretic peptide (LANP), vessel dilator (VDL), kaliruretic peptide (KP), or atrial natriuretic peptide (ANP).

ANP was found to provide the best anti-cancer effect, eliminating tumors in four of five treated mice. Among those not fully cured, VDL provided the best cancer reduction -- bringing exposed tumors down to just 2 percent of their largest size.

After a year, the researchers found that all the cured mice remained cancer-free. Based on the fact that the normal life span for a mouse is about one year, Vesely and his colleagues concluded that all the treated mice ended up dying of old age, not cancer.

Vesely, who noted that his wife died of breast cancer about five years ago, then turned his focus to that cancer.

He said that in similar mouse experiments, treatments with VDL and KP hormones both produced a 67 percent tumor elimination rate.

"We never expected results this good, of course," he said. "And I don't want to get too carried away here. But if this works in humans, it would be spectacular. Because, of course, one out of every two families [experiences] cancer."

Human trials -- funded by the private San Diego-based firm Kalos Therapeutics -- are to begin within 12 to 18 months. If all goes well, Vesely predicted that a hormone treatment could become available within three years.

However, Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, cautioned that while the notion of a heart hormone cancer treatment has a "seductive" appeal, much more research is required.

"Unfortunately, in general, we see a lot of experiments that seem promising in test tubes and animals but for whatever reason don't translate into anything that has treatment benefit," he said. "And specifically, in this case, we're talking about normal hormones already in circulation in our body, and normal receptors on cancer cells.

"So, in a perhaps simplistic, but nonetheless important, way, the question then arises: Why do people get cancer in the first place if this hormonal mechanism is so effective?" Lichtenfeld said. "And I do not see that the researchers clearly suggest an underlying rational mechanism to explain why this would happen and work in humans.

"So, I understand here that a researcher has lost a wife and a mother to cancer, and I know it's personal," he acknowledged. "And I've certainly learned to never say never. But it would take considerably more replication of this work before I could say this theory will gain traction."

More information
For additional information on current cancer treatment options, visit the American Cancer Society.


Balancing Your Hormones Without Drugs... You Can Feel Good Again

Balancing Your Hormones Without Drugs... You Can Feel Good Again

$19.95
[ learn more ]

Add to Cart

Hormone imbalance can be reversed! Look and feel better than ever, just take the time to learn about yourself and read the information contained in this just released e-book about reversing hormone imbalance. Are you ready to finally look and feel great? If so... read on... - E-Book Version.(BH)

Sunday, February 24, 2008

BSD Medical Participates on Invitation at International Conference on Hyperthermic Oncology and Medicine in India

BSD Medical Corporation (AMEX:BSM) today announced that Richard A. White, Vice President of International Sales, along with some of the leading researchers in hyperthermia therapy, spoke and participated in a panel discussion as invited guests at the International Conference on Hyperthermic Oncology and Medicine held at the Mahavir Cancer Center in Patna, India February 16-17.

The two-day meeting was devoted entirely to the use of hyperthermia therapy in treating cancer. The panel upon which Mr. White and international scientists from the field participated was centered upon strategies to bring hyperthermia therapy to developing countries. At the meeting the invited scientists spoke on the clinical support for the use of hyperthermia therapy in treating cancer, as largely performed on BSD Medical's hyperthermia systems.

The conference received strong attention from the Indian Government, as Her Excellency, the President of India, Shrimati Pratibha Devisingh Patil opened the conference. The President said, "Cancer can be controlled if diagnosed well in time, however, in India, about two-thirds of cancer patients are diagnosed at the advanced stage when it becomes more difficult to treat."

GA_googleFillSlotWithSize("ca-pub-5440138744487553", "News_Main_300x250", 300, 250);
Dr. Nagraj Huigol, the National Secretary of the Association of Hyperthermic Oncology and Medicine (in India), stated that "Hyperthermia could be beneficial even for those suffering from resistant cancers. In fact a combination of the conventional mode of treatment and hyperthermia could create wonders if handled aptly." Dr. Nagraj appealed to the central and state governments to set up prominent medical centers for the benefit of those cancer patients who have lost all hope.

More than 800,000 people in India are diagnosed with cancer every year, and more than 400,000 die from the disease annually. Of these, lung cancer (250,000 cases), cervical cancer (126,000 cases) and breast cancer (80,000 cases) are the most prevalent. About 70% of the cases are diagnosed when the cancer is in an advanced T3 or T4 stage, where the use of hyperthermia therapy may be particularly implied for some cancers.

About BSD Medical Corporation
BSD Medical Corp. is the leading developer of systems used to deliver hyperthermia therapy for the treatment of cancer. Hyperthermia therapy is used to kill cancer directly and increase the effectiveness of companion radiation treatments. Research has also shown promising results from the use of hyperthermia therapy in combination with chemotherapy, and for tumor reduction prior to surgery. For further information visit BSD Medical's website at http://www.bsdmedical.com/ or BSD's patient website at http://www.treatwithheat.com/.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

Source: Business Wire

Monday, February 18, 2008

Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too

HealthDay News) -- It's clear that chemotherapy after breast cancer surgery increases survival rates. But many older women aren't being offered this potentially lifesaving treatment.
But, age shouldn't be a deciding factor -- an older woman's general health appears to be a better predictor of positive results after chemotherapy, according to a study published recently in the Journal of the American Medical Association.

"Age alone should not be a contraindication to the use of optimal chemotherapy regimens in older women who are in good general health," the study authors said.

About half of all breast cancers in the United States occur in women older than 65. Past studies have shown that chemotherapy after breast cancer surgery increases the odds of disease-free survival in women between the ages of 50 and 69. But little information has been available for treating women over 70, the study authors said.

One important concern is that older women may experience more toxic side effects from chemotherapy. That's because the kidneys often function less effectively with age, and there's not as great a bone marrow reserve for generating new blood cells in older people.

"There's always been a concern that older women with breast cancer might be under-treated," said Dr. Yelena Novik, an oncologist at New York University Medical Center in New York City. "In clinical trials, the proportion of women over 70, and especially over 75, is very small, so it's hard to know the benefits and the risks. It's understood that older women are more likely to have other medical problems, such as heart disease, hypertension and diabetes, so the question is, should they be offered the same treatment as younger women?"

To answer that question, researchers from cancer centers around the country reviewed data from four previous trials that included almost 6,500 women with lymph-node positive breast cancer. Five hundred and forty-two of the women in the studies were over 65, and 159 were over age 70.

Each of the studies looked at various doses and regimens of chemotherapy, including regimens considered to be potentially more toxic than the others.

A number of factors influenced survival rates, including smaller tumor size, fewer positive lymph nodes, having more chemotherapy, and using the breast cancer drug tamoxifen. Age alone, however, didn't appear to influence survival rates, the study authors found.

Women over 65 were more likely to die of causes other than breast cancer. And they were slightly more likely to die as a result of the treatment than younger women were. Overall treatment-related mortality was 0.5 percent, and 1.5 percent for those women over 65.
"What this study basically showed is that we shouldn't prejudice our treatment decisions based on chronological age," said Dr. Jay Brooks, chairman of hematology and oncology at Ochsner Health System in Baton Rouge, La. "We have a lot of very healthy, older individuals, and to simply preclude someone from taking potentially lifesaving therapy because they've reached some chronological age is just wrong. Would you tell someone who's 68 with coronary vessel disease not to get a bypass?"

Both Novik and Brooks said that recent advances in tailoring breast cancer treatments to the individual patient have likely made the age disparity less of an issue.

"We're hopefully getting smarter in understanding cancer behaviors, which gives us better insight into which drugs to use," Novik said.

Brooks advised older women with breast cancer to "sit down and talk with their doctor about what their individualized risk of recurrence is. We have good tools to offer individualized treatment options, whatever your age."

More information
To learn more about chemotherapy treatment for breast cancer, visit the American Cancer Society.

Saturday, December 15, 2007

Breast Cancer Genes Also Raise Men's Risk for Malignancy

(HealthDay News) -- Men whose mothers, sisters or daughters test positive for a breast cancer-causing mutation in the BRCA1 or BRCA2 genes may also have the mutation and be at increased risk for cancer, a new study finds.

Most of those men are unaware of the danger, noted researchers at Fox Chase Cancer Center in Philadelphia, who examined how families discuss genetic test results.

Men with a mutation in the BRCA1 or BRCA2 genes have a 14 percent lifetime risk of developing prostate cancer and a 6 percent lifetime risk of developing breast cancer, the study authors said.

"Despite these health implications, we have found a lack of understanding of genetic test results among men in these families," study lead author Dr Mary B. Daly, senior vice president for population science at Fox Chase, said in a prepared statement.

The researchers interviewed 24 men with a first-degree female relative who tested positive for a BRCA1 or BRAC2 mutation. All the women said they told their male relative about the test results, but only 18 of the men remembered that they were told.

About half the men (7) who did remember being told the test results didn't believe that they also had an increased risk of cancer. Only 5 of the men correctly assessed their chance of having a BRCA1 or BRCA 2 mutation.

"We devote a significant amount of time learning how best to communicate genetic test results to women, but this study shows we also need to help them communicate the information to their male family members who may be impacted by the test results," Daly concluded.

The study was expected to be presented Friday at the San Antonio Breast Cancer Symposium.

More information
The U.S. National Cancer Institute has more about cancer genetics.

Sunday, October 28, 2007

Precancerous Lesions Raise Cervical Cancer Risk

(HealthDay News) -- Women who have had advanced precancerous lesions of the cervix are still at risk for invasive cancers up to 25 years later, Swedish researchers report.

Currently, the American Cancer Society recommends that women who have had precancerous lesions called severe dysplasia/carcinoma in situ (CIS) continue getting Pap tests for 10 years after treatment. But, based on this study, these guidelines may need to be changed, said Debbie Saslow, the society's director of breast and gynecologic cancer, who was not involved with the research.

Saslow added, however, that even though these women continue to be at risk for developing cervical or vaginal cancer, the risk is low. "Women who have been treated for advanced precancer do need to remain vigilant," she said.

"This paper is going in my file for when we update our guidelines in the next two years," Saslow added. "We will see if we want to stick with 10 years or go to a much wider interval."

The study was led by Dr. Bjorn Strander, a senior consultant with the Department of Obstetrics and Gynecology at Sahlgren's Academy at the University of Gothenburg. The researchers collected data on 132,493 women who had a diagnosis of severe dysplasia/CIS between 1958 and 2002. The statistics came from the National Swedish Cancer Register.

The researchers found 881 women had developed cervical cancer, and 111 had developed vaginal cancer more than one year after the initial diagnosis. This was almost seven times higher than expected, the researchers said.

Women with a diagnosis of severe dysplasia/CIS were more than twice as likely to develop cancer compared with the general female population. The women were also twice as likely to develop invasive cervical cancer after diagnosis of CIS if that diagnosis was made between 1991 and 2000, compared with the same diagnosis made from 1958 to 1970. This increased risk might be due to changes in treatment over that period, particularly because fewer hysterectomies are being done as part of treatment for CIS, the study authors said.

Strander's team also found a particularly high risk for women over age 50, and this risk continued to increase with age. "The risk after treatment hardly decreases at all after treatment and is still sustained after more than 25 years," he said.

"While well-screened women after 50 to 60 years of age are very well protected from cervical cancer and have little, if any, further use of screening, this does not apply to women who have been treated for grade 3 CIS," Strander said. "They need, and should have, long-term follow-up, perhaps lifelong," he said.

The results are published in the Oct. 26 edition of the British Medical Journal.

More information
For more on cervical cancer, visit the American Cancer Society.

Tuesday, October 02, 2007

Advantages and Disadvantages of Alcohol Intake on Cardiovascular Health Reviewed

News Author: Laurie Barclay, MD
CME Author: Charles Vega, MD

The latest American Heart Association guidelines caution people not to start drinking alcohol if they do not already drink alcohol, according to a review of the advantages and disadvantages of alcohol intake on cardiovascular health published in the August 23 Online First issue of the Journal of the American College of Cardiology.

"Accumulating scientific evidence indicates that light to moderate drinking done on a daily basis may significantly reduce the risks of coronary heart disease (CHD) and all-cause mortality," write James H. O'Keefe, MD, FACC, and colleagues from the Mid America Heart Institute in Kansas City, Missouri. "In contrast, excessive alcohol intake and binge drinking are toxic to both the heart and overall health and are the third leading cause of premature death among Americans.

The purpose of the present review is to:
1) outline the specific benefits and risks of alcohol, and the threshold of intake at which drinking becomes a health danger rather than an advantage;
2) detail the mechanisms whereby alcohol confers cardioprotection; and
3) discuss the ideal quantities, drinking patterns, and beverages, and which individuals are most likely to benefit."

Research to date has shown J-shaped relationships between alcohol consumption and several adverse health outcomes, including all-cause mortality, CHD, diabetes, hypertension, congestive heart failure, stroke, dementia, and Raynaud's phenomenon.

Some cardioprotective benefits have been demonstrated for light to moderate alcohol consumption (up to 1 drink daily for women and 1 or 2 drinks daily for men). Most studies have shown that light to moderate drinking is associated with risk reductions for CHD of approximately 30% to 35%.

Alcohol consumed in moderation seems to have an antiatherosclerotic effect, with decreased incidence of peripheral arterial disease and decreased atherosclerotic burden shown by coronary angiography, computerized tomography-detected coronary calcium, and carotid ultrasound.
Like exercise, alcohol consumption seems to be most cardioprotective when done daily and in moderation. However, increasingly excessive consumption is associated with proportional worsening of outcomes.

Because of the beneficial effects on high-density lipoprotein (HDL) cholesterol, insulin action, and inflammation, light to moderate alcohol intake may be particularly helpful for patients with abnormal glucose metabolism and/or insulin resistance. Light to moderate alcohol intake may be associated with reductions in the prevalence and incidence of diabetes, and a large meta-analysis with 12-year follow-up showed a 30% reduction in new diabetes in those who consumed 1 to 2 drinks daily.

The cardiovascular benefits associated with alcohol consumption protection are thought to be mediated by improvements in insulin sensitivity and HDL cholesterol. The major protective component seems to be the ethanol itself, and not the other ingredients found in different types of alcoholic beverages.

In a meta-analysis incorporating data from more than 1 million participants, consumption of 1 drink daily by women and 1 or 2 drinks daily by men was associated with an 18% reduction in total mortality, but daily intakes of more than 2 drinks in women and 3 drinks in men were associated with dose-dependent increased mortality.

Although low-dose, daily alcohol consumption has been linked to better health than less frequent use, binge drinking increases cardiovascular events and mortality, even in otherwise light drinkers.

"Alcohol should not be universally prescribed for health enhancement to nondrinking individuals owing to the lack of randomized outcome data and the potential for problem drinking," the study authors note. "Alcohol (ethanol) consumption is analogous to the proverbial double-edged sword, and perhaps no other factor in cardiovascular (CV) health is capable of cutting so deeply in either direction depending on how it is used."

Guidelines from the United Kingdom suggest that middle-aged or elderly men and postmenopausal women who drink seldom or never might consider the possibility that light drinking would benefit their health. On occasion, the reviewers have made a similar recommendation to patients who do not smoke and who have no personal or family history of substance abuse and no history of depression or bipolar disorder. However, they argue that light to moderate drinking should not be universally recommended to the general public or even to patients with cardiovascular disease.

As an analogy, they point out that observational data and findings from randomized trials using surrogate endpoints suggested that hormone replacement therapy for women and antioxidant vitamins improved cardiovascular outcomes, whereas later randomized trials with larger samples led to the opposite conclusions. They note that no randomized trials of alcohol for improving clinical outcomes have yet been performed. In observational studies, residual unmeasured confounding factors could be contributing to apparent benefits that seem to be associated with light to moderate drinking.

The investigators further note that heavy drinking has caused significant individual and societal problems and morbidity. In the past 15 years, the rates of alcohol abuse and binge drinking have been increasing, according to the findings of some studies. Alcohol abuse causes 100,000 deaths each year in the United States, and it has been deemed the third largest preventable cause of death.

Excessive alcohol consumption has been associated with increased risks for all-cause mortality, motor vehicle crashes, stroke, cardiomyopathy, cardiac dysrhythmia, sudden cardiac arrest, suicide, cancer (particularly of the breast and gastrointestinal tract), cirrhosis, fetal alcohol syndrome and sleep apnea.

"Sobering statistics warn that moderate daily drinking is a slippery slope that many individuals cannot safely navigate," the study authors conclude. "The latest American Heart Association guidelines caution people not to start drinking if they do not already drink alcohol, because it is not possible to predict in which people alcohol abuse will become a problem. Until we have more randomized outcome data, and tools for predicting susceptibility to problem drinking, it would seem prudent to encourage physicians and patients to focus on more innocuous interventions to prevent CHD."

J Am Coll Cardiol. Published online August 23, 2007.
2007;50:1009-1014.

Monday, August 13, 2007

Most Asian Men Have Better Prostate Cancer Survival Rates

(HealthDay News) -- Your prognosis for surviving prostate cancer may depend on your racial and ethnic background, a new study suggests.

Asian men have better survival rates than white males, while South Asians have the worst survival rates, according to results of a study of men living in California.

"Nearly all Asians do far better when they get prostate cancer," said study lead author Dr. Anthony Robbins, of the California Cancer Registry in Sacramento. "But Indian men didn't do as well as other Asian men, and they did worse than all other men, including blacks and whites," he added.

The reasons for these racial and ethnic differences in prostate cancer survival aren't known, Robbins said, adding, "We just couldn't explain it."

Not only couldn't the researchers explain the finding, they were left with an apparent paradox. The Asian men were usually older and had more advanced disease at the time of diagnosis, Robbins said. "Based on their risk factors, you would think they were going to do worse," he said.

In the study, Robbins and his colleagues collected data on 116,916 men (108,076 whites and 8,840 Asians from the six largest represented Asian ethnicities -- Chinese, Filipino, Japanese, Korean, South Asian, and Vietnamese) diagnosed with prostate cancer. The researchers compared prognostic factors and survival rates among the men.

The researchers found that for Asians, risk profiles were worse compared with whites. For example, Asians were more likely to have more advanced disease and use non-curative therapies. But, for Asians -- except for South Asians -- survival rates were equal to or better than rates for whites.

Japanese-American men were 34 percent less likely to die from prostate cancer compared with whites. But South Asian men -- those from India, Pakistan, Bangladesh, Sri Lanka, Nepal, and Bhutan -- were 40 percent more likely to die from the disease, Robbins said.

The study was published online Monday in the journal Cancer.

Some of the factors that may influence the findings include diet, exercise and genetics, Robbins speculated.

"Doctors that are seeing patients for prostate cancer need to be aware that these differences can be used as factors in planning the patient's treatment and telling the patient what their survival might be," Robbins said.

Dr. Durado Brooks, director of prostate and colorectal cancer at the American Cancer Society, thinks this study demonstrates the need to better understand how different racial and ethnic groups respond to diseases.

"This study points out the potential misleading conclusions we can come to when we use these large groups to lump different subpopulations into," he said.

"If you lump in the South Asian subgroup with other Asians, as is traditionally done, you totally miss the fact that these folks have a strikingly higher chance of dying from prostate cancer," Brooks said.

Brooks said the study finding can provide a basis for research to try to understand why these differences exist between populations.

Prostate cancer is the most common type of cancer to strike American men, other than skin cancer, according to the American Cancer Society, which estimates there will be about 218,890 new cases of prostate cancer in the United States in 2007, and about 27,050 men will die of the disease. Prostate cancer is the second leading cause of cancer death in males. While one in six men will get prostate cancer during his lifetime, only one man in 34 will die of the disease. The death rate for prostate cancer is declining, due in large part to earlier diagnoses, the society said.

Another paper in the same issue of the journal also found racial differences among women who survive breast cancer; with black women having poorer survival regardless of the stage of the disease.

It is known that black women had larger tumors and are more likely to have invasive breast cancer. But the study, lead by Dr. Alfred Neugut from Columbia University Medical Center and Russell McBride from Mailman School of Public Health, found that mortality among black women was up to 56 percent higher than whites.

Neugut's team says that the disparities in survival were surprising and suggest that non-clinical factors, such as access to and quality of care, may play a part.

More information
For more on prostate cancer, visit the American Cancer Society.

Wednesday, April 18, 2007

Breast Cancer Vaccine Shows Promise

(HealthDay News) -- U.S. scientists say they've developed a breast cancer vaccine that stimulates a powerful immune system response to tumor cells.

In mice, the "synthetic peptide" vaccine stimulated an anti-tumor T-cell response that identified and prevented the spread of breast cancer cells. T-cells are white blood cells that play an important role in immune response.

A team at the Mayo Clinic in Rochester, Minn., tested the vaccine on female mice that had the cancer-producing oncogene HER-2/neu. The mice received the vaccine at the early stage of tumor development.

The vaccine either slowed or stopped the progression of breast cancer in all the mice, the team reported Tuesday at the annual meeting of the American Association for Cancer Research in Los Angeles.

Because synthetic peptides alone do not usually trigger a strong immune response, the vaccine was given in combination with a "Toll-like receptor" stimulant, which mimics the way invading bacteria would spur the immune system into action.

"We found that we could train the immune system to recognize these synthetic peptides as dangerous foreign agents of the HER-2/neu gene by mimicking what the bacteria would do in your body. The body responded by killing everything that expressed HER-2/neu in high amounts," study author Dr. Pilar Nava-Parada said in a prepared statement.

Using this approach, it would likely take only one immunization to build an immune system response powerful enough to destroy a tumor.

To date, attempts at creating effective cancer vaccines have produced mixed results. This and other new studies suggest that scientists are moving closer to creating viable cancer vaccines, the Mayo researchers said.

More information about breast cancer.

more discussion: Forum
· Addiction Forum · Ask the Doctors Forum · Ayurveda Forum · Ayurvedic & Thai Herbs Forum · Colon Cleansing Forum · Dental Forum · Diabetes Forum · Diet Forum · General Cleansing Forum · Hepatitis A, B. C Forum · Integrated Medicine Forum · Live Blood Analysis Forum · Ozone-Oxygen-Forum · pH - Alkaline - Acidity Forum · Weight Loss Forum

Monday, March 19, 2007

Male Breast Cancer Deadlier for Blacks

Male Breast Cancer Deadlier for Blacks

(HealthDay News) -- Black men are more likely than white men to die of breast cancer, concludes a study that urges more research into racial disparities in male breast cancer.

Male breast cancer accounts for less than 1 percent of all breast cancers and less than 1 percent of all cancers in men, according to background information in a news release about the study.

In 2006, about 1,700 men were diagnosed with breast cancer in the United States, and the disease killed about 400 men.

The incidence of male breast cancer has been rising, increasing about 60 percent between 1990 and 2000.

In the study, researchers at Columbia University, New York City, studied 510 men over age 65 who were diagnosed with stage 1-3 breast cancer between 1991 and 2002.

Five-year survival rates were about 90 percent for the 456 white men in the study and 66 percent for the 34 black men.

The findings are reported in the March 20 issue of the Journal of Clinical Oncology.

"Racial disparities in outcomes in women with breast cancer have been well studied. This study shows that similar racial disparities exist for men. While male breast cancer is rare, understanding the factors that black men and women with breast cancer have in common may help us understand the reasons for these disparities," study senior author Dr. Dawn L. Hershman, an assistant professor of medicine and epidemiology at Columbia's Herbert Irving Comprehensive Cancer Center, said in a prepared statement.

"These findings support more investigation into the clinical and biologic factors that contribute to racial disparities in male breast cancer. While many different factors are likely to be involved in the disparity, this study provides some clues that lower access to standard treatment may be an important one," Hershman said.

More information
The American Cancer Society has more about male breast cancer.

more discussion: Forum
· Addiction Forum · Ask the Doctors Forum · Ayurveda Forum · Ayurvedic & Thai Herbs Forum · Colon Cleansing Forum · Dental Forum · Diabetes Forum · Diet Forum · General Cleansing Forum · Hepatitis A, B. C Forum · Integrated Medicine Forum · Live Blood Analysis Forum · Ozone-Oxygen-Forum · pH - Alkaline - Acidity Forum · Weight Loss Forum

Researchers Seek More Women for 'Sister Study' of Breast Cancer

(HealthDay News) -- So far, more than 33,000 American women have joined the Sister Study, a research effort to uncover the causes of breast cancer.

But the study is still looking for another 17,000 more women to reach its enrollment target of 50,000 women by the end of 2007, according the U.S. National Institute of Environmental Health Sciences (NIEHS).

The study is enrolling women, aged 35 to 74, whose sisters were diagnosed with breast cancer. The women who join the study must never have been diagnosed with breast cancer. The 10-year observational Sister Study was launched in October 2004.

"Many women have heard about the Sister Study, but they haven't signed up yet, and we really need them now," principal investigator Dale Sandler, chief of the epidemiology branch at the NIEHS, said in a prepared statement.

"Doctors know very little about how the environment may affect breast cancer, that is why the Sister Study is so important. We hope women will make that call today," Sandler said.

The Sister Study, which is available in English and Spanish, doesn't require a major time commitment from participants. When they enroll, they answer questions about diet, job, hobbies, and things they've been exposed to throughout their lives. Later, they'll be asked to give small samples of blood. urine, toenail clippings and house dust.

More information
You can learn more by going to the Sister Study Web site, which is also available in Spanish.

Friday, January 26, 2007

Sauna Therapy and Healing

Fever
A fever is the body's highly evolved attempt to destroy invading organisms and to sweat impurities out through the skin Fever is an effective natural process of curing disease and restoring health, heat therapy, or hyperthermia, represents a way to create fever to call out his natural healing process.

Heat Therapy
The Secret of Hyperthermia, or heat therapy, is that cancer cells are vulnerable to high temperatures. Heat the cancer cells and they can be easily destroyed, especially if the tumor lies close to the skin surface. In the process, patients can reduce or even eliminate the need for radiation.

The Principle
The principle behind hyperthermia is simple: heat cancer cells and they can be killed easily. Direct killing of cancer cells begin to occur when the cancerous tissue reaches about 104 F to 105.8F. Only a relatively small rise in body temperature can make a huge difference says Dr. R Atkins who includes heat therapy in his cancer protocols.

Unlike normal tissue, tumors have poor blood flow relative to their metabolic needs and cannot dissipate the heat, so they tend to get hotter than the surrounding area. Rapidly dividing cells (i.e., cancer cells) are more vulnerable to the effects of heat. Normally, part of the damage caused by radiation is repaired by the cancer cells, enabling some to survive; however, heat foils this self-repair ability. Taken together, these facts tend to make tumors more vulnerable to heat treatment than normal cells. Hyperthermia is now approved in the U.S. for treatment of breast cancer recurrence.

Detoxification
Practitioners of alternative medicine have long recognized hyperthermia as a useful technique in detoxification therapy because it releases toxins stored in fat cells. Hyperhtermia can be used to remove fat-stored chemicals such as pesticides, PCBs, and drug residues from the body. Only recently ha conventional medicine caught up with this practice and begun to incorporate hypertheria in the orthodox treatment protocols for cancer.

more info at:
http://www.dreddyclinic.com/integrated_med/ozone_oxygen.htm

Wednesday, November 08, 2006

Scientists Probe Radiotherapy-Linked Brain Changes

(HealthDay News) -- Researchers believe certain brain changes may be linked to the dementia experienced by many cancer patients after whole-brain radiation treatment.

Each year, about 200,000 people in the United States receive whole-brain radiation, which is used to treat recurrent brain tumors as well as to prevent breast cancer, lung cancer, and malignant melanoma from spreading to the brain.

About a year after whole-brain radiation treatment, up to 50 percent of patients develop progressive learning and memory problems.

In their research with rats, a team at Wake Forest University School of Medicine in Winston-Salem, N.C., found that whole-brain radiation caused compositional changes in brain cell receptors for the neurotransmitter glutamate.

A neurotransmitter carries signals between brain nerve cells. The changes in these receptors appear to be associated with cognitive problems.

"By identifying exactly how radiation causes these side effects, our hope is that we can find a way to prevent or reverse them," study lead author and research fellow Lei Shi explained in a prepared statement.

The findings were presented Monday at the annual meeting of the Radiation Research Society, in Philadelphia.

"There is growing concern about the cognitive consequences of whole-brain radiation. Our findings suggest that very subtle changes may be critical and that glutamate receptors may be one of those changes," Wake Forest senior researcher Judy Brunso-Bechtold, professor of neurobiology and anatomy, said in a prepared statement.

More information
The U.S. National Cancer Institute has more about whole-brain radiation.

Friday, October 20, 2006

Older Women Not Getting Proper Breast Cancer Treatment

(HealthDay News) -- Many older women with breast cancer are being under-diagnosed and under-treated, especially in community hospitals, researchers report.

The problem is taking on added urgency because breast cancer is becoming more common as the U.S. population ages. Almost 50 percent of women with breast cancer are 65 and older, and 35 percent are older than 70. And 77 percent of deaths from breast cancer involve women over 55, the researchers noted.

Yet many older women appear to be under-diagnosed and under-treated, perhaps because they may have other serious life-threatening medical conditions. In addition, there's confusion about when or if to screen older women for breast cancer. Some guidelines suggest that women stop having mammograms at 70, while others offer no upper limit.

In the report, published in the October issue of the Archives of Surgery, Drs. David A. Litvak and Rajeev Arora of Michigan State University looked at the medical records of 354 women aged 70 and older who were diagnosed with breast cancer in a community hospital between 1992 and 2002.

The doctors found that 46 percent of the women had breast cancer that could be detected during a physical examination. In addition, even though 72 percent of the women had mammograms, the tests were mostly administered to verify the results of the physical exam. In fact, mammograms found only 54 percent of undiagnosed breast cancers.

For 70 percent of the women, the cancer was in the early stages. But 36 percent of the women and 56 percent of those 80 or older were never examined to see if the cancer had spread to the lymph nodes.

In terms of treatment, the doctors found that about 50 percent of the women had breast-conserving surgery. However, the rates of women getting chemotherapy, radiation and hormonal therapy after surgery were lower than expected and lowest among the oldest women.

And many women who were candidates for adjuvant therapy, including those whose cancer had spread to lymph nodes, were not given this additional therapy. Of the 20 percent of women whose cancer had spread to the lymph nodes, only 29 percent received chemotherapy.

Moreover, only 17 percent of the women 80 or older whose cancer had spread received chemotherapy. This rate was significantly lower than for women under 80, noted Arora and Litvak, who is now at the Kaiser Permanente Medical Center in Orange County, Calif.

"There are misconceptions by the public and the medical community that it's OK to omit certain diagnostic tests or treatments in older patients," Litvak said. "Older people are in a special category, which means that we have to be careful about how we treat them and how we approach their cancer."

Litvak and Arora believe that older patients should receive a geriatric assessment that would help estimate life expectancy and predict tolerance to cancer treatment. In addition, screening programs should be based on an individual geriatric assessment.

"The bottom line is that we really have to start individualizing the care of older patients," Litvak said. "It doesn't make sense to have a cap on mammograms for age. It should be based on the patient's overall health and their life expectancy. The same is true for treatment."

"Most older patients tolerate and benefit from the same treatments that younger patients get," Litvak added. "You just have to be careful about how you give it."

One expert thinks not enough is known about the risks and benefits of treating breast cancer in older women.

"This is not a surprising finding," said Dr. Alan Astrow, director of hematology/oncology at Maimonides Medical Center in New York City. "But we really don't know how best to treat older women with breast cancer."

For example, Astrow said, it's not known if withholding chemotherapy from older women shortens life. "Most oncologists feel that the side effects of chemotherapy in women over 80 would outweigh the benefits," he said.

Astrow thinks studies are needed to determine the value of breast cancer treatment for older women. "It could have an important public health impact," he said. "If, in fact, we are under-treating, and under-treating leads to worse outcomes, then that's something we really need to address because it affects a large number of women."

More information
The American Cancer Society can tell you more about breast cancer and older women

Sunday, September 17, 2006

Protein Screen Predicts Breast Cancer Therapy Success

(HealthDay News) -- A new test may help identify which breast cancer patients are most likely to benefit from chemotherapy.

The test, called OncoPlan, is already commercially available, and it has been shown to predict the aggressiveness of tumors and disease recurrence after surgery in breast, colon and stomach cancers. Now researchers believe it may help predict which breast cancer patients would benefit most from chemotherapy.

In a study presented at the first meeting on Molecular Diagnostics in Cancer Therapeutic Development, researchers looked at the two forms of protein measured by OncoPlan in 2,380 women with breast cancer, 717 of whom had undergone chemotherapy.

They found that the women who had low levels of one of the proteins and did not receive chemotherapy had very poor outcomes. The same women who did receive chemotherapy, however, had a twofold reduced risk of relapsing and dying from their disease.

The women who had high levels of the protein were much more likely to survive their disease, and appeared to derive no additional benefit from chemotherapy.

More research is needed to clarify the ability of OncoPlan in predicting outcomes of chemotherapy.

"But even at this point, the results are very exciting because, with further validation in clinical trials, OncoPlan, which is already being used to predict disease aggressiveness, will help to ensure that individual patients receive the most beneficial therapies," study author A. Raymond Frackelton Jr., an associate professor at Brown University and vice president of Research at Catalyst Oncology (the company marketing OncoPlan), said in a prepared statement.

More information
The National Cancer Institute has more about breast cancer.

Wednesday, September 13, 2006

Exercise May Help Breast Cancer Patients Survive

(HealthDay News) -- Women who are physically active in the year before they receive a diagnosis of breast cancer are more likely to survive the disease, a new study finds.

"We found a beneficial effect on survival for exercise undertaken in the year before diagnosis, particularly among women who were overweight or obese near the time they were diagnosed with breast cancer," said study author Page Abrahamson, a postdoctoral researcher at the Fred Hutchinson Cancer Research Center in Seattle.

Abrahamson led the research while at the University of North Carolina, Chapel Hill.
The study is published in the Oct. 15 issue of Cancer.

In the study, Abrahamson's team analyzed data on nearly 1,300 women ages 20 to 54 who were diagnosed with invasive breast cancer between 1990 and 1992. They asked the women about their average frequency of moderate and vigorous physical activity when they were age 13, 20 and during the year before their diagnosis.

An abundance of regular exercise before diagnosis was associated with improved disease outcomes. The association was particularly strong for women with a body mass index (BMI) of more than 25 -- the statistical threshold for overweight -- who also reported the highest levels of physical activity in the one year before their diagnosis. (For reference, a woman 5 feet 5 inches tall who weighs 150 pounds has a BMI of 25.)

Overall, women with rated in the highest 25 percent, in terms of their level of activity, were 21 percent more likely to survive than those rated in the bottom quarter. The benefits for women with BMIs above 25 who had high levels of activity rose; they were 30 percent less likely to die than those with BMIs above 25 who engaged in low levels of activity.

Activity in the teen years or early adulthood did not have an impact on survival, the researchers said.

"We were not able to evaluate detailed, long-term exercise," Abrahamson said. "However, exercise levels in the year before diagnosis is likely an indicator of a person's average adult exercise patterns."

While much other research has suggested that exercising regularly reduces the risk of getting breast and other cancers, less is known about what effect activity has on a woman's prognosis if and when she gets breast cancer.

One previous study found a beneficial effect of exercise for both ideal-weight women and overweight women diagnosed with breast cancer, Abrahamson pointed out.

Exactly why this study did not show much benefit for normal-weight women isn't known, she said. "This is difficult to explain. It is possible that our finding is a fluke and that improved survival would apply to all women with breast cancer."

Another theory revolves around weight-linked differences in circulating estrogen.
Exercise is known to lower estrogen levels, Abrahamson said. "Once women receive radiation or chemotherapy after diagnosis, they no longer produce hormones from their ovaries. Therefore, lower-weight women wouldn't necessarily gain extra benefit from exercise," she said.

"However, for overweight women, they are still getting hormones from their excess fat tissue and are at a higher risk of dying. It is possible that overweight women who are exercising are lowering their hormone levels through exercise and increasing their odds of surviving," the Seattle researcher said. "Previous studies have shown exercise to significantly decrease estrogen levels in overweight women."

"This study adds another piece to the puzzle," said Alpa Patel, director of the Cancer Prevention Study-3 for the American Cancer Society, in Atlanta. "We know that lifelong physical activity reduces the risk of breast cancer, and some studies show even initiating the exercise in adulthood [reduces risk]."

Now, she added, this study shows that physical activity before a diagnosis of breast cancer may help women survive.

Another expert said the study does have its flaws.

Leslie Bernstein, professor and chair of cancer research at the University of Southern California's Keck School of Medicine, said "the study suffers from the problem that the activity refers to only activity prior to diagnosis of beast cancer," she said, rather than lifetime activity.
"When we looked at this same issue in a similar design, but with measures of activity across the lifespan up to the date of diagnosis, we saw no impact of exercise activity on the risk of dying or overall mortality."

Still, Bernstein said exercise certainly can't hurt, and may help.

"I would recommend that women with breast cancer begin to participate in an exercise program, one that is carefully considered by their physicians, considering any [other diseases] they might have," she said

In the same issue of the journal, U.S. researchers say they've developed a screening method that spots patients at risk for hereditary breast cancer.

Called PAT, for "pedigree assessment tool," it was designed by physicians at the OSF Saint Anthony Center for Cancer Care in Rockford, Ill. PAT is meant to be used by general-practice physicians. It collects data about family history and other information, then totals the score, with a score of 8 or more indicating a heightened risk for breast cancer.

More information
To learn more about breast cancer, visit the American Cancer Society.

Thursday, September 07, 2006

Home Visits Boost Mammography Rates for Rural Poor

(HealthDay News) -- Trained lay health advisers can dramatically boost the number of rural, low-income American women who get mammography screening for breast cancer, a new study concludes.

Rural, poor and minority women are less likely than other women to have mammograms, the researchers noted.

The four-year study began in 1998 and included 851 low-income white, black and Native American women in rural North Carolina who had not had a mammogram in the previous year.
Each women filled out a survey about her knowledge of breast and cervical cancer screening and were randomly assigned to a group that received home visits from a lay health adviser or to a comparison group.

The women in the comparison group received a letter and a brochure about the need for regular cancer screening. The women in the intervention group received three in-person home visits from a lay health adviser over nine to 12 months.

During the visits, the advisers talked to the women about breast cancer, mammography, breast self-exam, and scheduling a mammogram. They also provided educations materials about cancer risk. Follow-up phone calls were made to the women to help them make mammography appointments and to encourage the women to discuss their mammogram experiences.

By the end of the study, 42 percent of the women in the intervention group had received a mammogram, compared to 27 percent of the women in the comparison group. This effect was noted in all three racial groups in the study.

"Our results show that lay health advisers can improve the rates of mammography screening among low-income, rural white, African-American and Native American women," principal investigator Electra D. Paskett, professor, College of Medicine and School of Public Health, Ohio State University, said in a prepared statement.

"The intervention improved knowledge and beliefs about mammography screening. We also empowered these women to realize that they can schedule a mammogram on their own, with or without encouragement from their doctors," Paskett said.

The findings are published in the Sept. 6 issue of the Journal of the National Cancer Institute.

More information
The U.S. National Cancer Institute has more about breast cancer screening.

Monday, July 10, 2006

Holocaust Survivors at Higher Long-Term Cancer Risk

(HealthDay News) -- A new study finds that rates of cancer and cancer-related death are especially high among survivors of the Holocaust in Israel.

An Israeli research team found that Holocaust survivors who emigrated from Europe to Israel following World War II are at higher risk for cancer compared to European Jews who moved there before the war began.

Much of the difference can be attributed to cancers found among the youngest Holocaust survivors. Specifically, male and female immigrants born in Europe between 1940 and 1945 faced the highest odds of developing breast or colorectal cancers, the researchers found.
While the findings may have implications for survivors of mass atrocities in general, they are of immediate concern to the 238,600 Holocaust survivors still living in Israel, said study co-author Dr. Micha Barchana.

"The bad news is that Holocaust survivors are at a higher risk to get cancer, but the good news is that we can do something [about it]," he said. "We are focusing on the practical implementation of the research results: the need for survivors to participate in early-detection programs that are offered in Israel as well as in most modern countries, due to the finding that classifies them as a high-risk population," he explained.

Barchana serves as the director of the National Cancer Registry in the Israeli Health Ministry and is also a senior lecturer in the school of public health at the University of Haifa in Israel.
He and his colleagues presented their research earlier this year at the International Agency for Research on Cancer, held in Lyon, France.

The work was funded by the Israel Cancer Society.
Barchana's team reviewed records from the Israeli government's Central Bureau of Statistics to first draft a list of all Jewish immigrants to Israel born in Europe between 1920 and 1945.
They then turned to the Israeli Health Ministry's National Cancer Registry to compile cancer incidence and death rates among these immigrants.

The researchers found that those immigrants born between 1920 and 1945 who came to Israel between the end World War II and 1989 were at significantly higher risk for cancer than immigrants born between 1920 and 1939 who migrated to Israel before the onset of World War II.

Barchana said his team does not know how many of the post-war European immigrants suffered through the experience of Nazi concentration camps or wartime Jewish ghettos. However, he said his team assumed that many or most did, and that, in any case, "all the Jews in Europe at war time had gone through severe food deprivation and other stresses."

Higher cancer risks seemed to linger for decades for this group, the researchers found. Male Holocaust survivors experienced a 14 percent higher cancer incidence rate than pre-war immigrants and were 2.4 times more likely to get cancer than their pre-war compatriots.

Female Holocaust survivors had a 21 percent higher rate of cancer than pre-war immigrants and were 2.3 times more likely to have a cancer diagnosis than pre-war immigrants.

Breaking down cancer incidence by specific diseases, the authors found that Holocaust survivors were at a significantly higher risk for lung cancer, Kaposi's sarcoma (a rare form of skin malignancy), and prostate cancer.

Heightened risks for certain other cancers stood out. For example, male Holocaust survivors were nine times more likely to be diagnosed with cancer of the large intestine than pre-war immigrants. Female Holocaust survivors faced more than double the risk for cancer of the large intestine and a 50 percent higher risk of developing breast cancer, the study found.

In addition, Barchana's team found that the younger the Holocaust survivor was during the war, the greater their risk for getting cancer. In fact, most of the increase in risk among Holocaust survivors was borne by those who were 14 years of age or younger during World War II.

Barchana said that finding has been shown in other studies involving survivors of terrible events. "Research on A-bomb survivors in Japan clearly shows that women that were at a young age are at higher risk of developing cancer later in life," he said. Similar data is emerging among those affected by the Chernobyl nuclear plant accident, Barchana added.

Patients who had survived the Holocaust also had a tougher battle to fight off the disease once it was diagnosed, the researchers found. According to Barchana, that may be due to the fact that "Holocaust survivors are being diagnosed at later stages compared to the control group."

Five-year cancer survival rates were 5 percent to 13 percent lower among Holocaust survivors compared to other immigrants, regardless of sex or age.

According to the researchers, the findings suggest that severe deprivation, from whatever cause, may weaken the body's long-term defenses against cancer. Inmates in the Nazi concentration camps suffered prolonged exposure to extreme poverty, food deprivation, over-crowding, harsh weather, physical abuse and mental stress.

The authors called for Holocaust survivors and their families to be increasingly vigilant about cancer detection, particularly for breast and colorectal cancers, and to avail themselves of the free screenings for such diseases that are currently available in Israel.

On a wider note, Barchana emphasized the role that food deprivation probably plays as a contributing factor to increased cancer risk.

"There has been some (prior) data on the possible role of malnutrition in breast cancer etiology," he remarked. "This work completes this knowledge, and this aspect of the study should be further investigated," Barchana said.

Dr. Michael Thun, vice president of epidemiology and surveillance research with the American Cancer Society in Atlanta, said the study was interesting and, in some ways, surprising.

"When one compares these results to studies of the Dutch Famine of 1944 to 1945, what they had found was that there was an increase in breast cancer risk, but they did not find the same increase in other cancers," Thun noted. "So, in this study, it was surprising to me that there was an increase in risk in colorectal cancer and a range of different cancers," he said.

"But in the case of the Holocaust, people had so many terrible things happen that it's even more complex and dreadful than just the famine resulting from war," added Thun. "So, I agree with the authors' conclusions that closer screening of these people is warranted to detect cancers early," he said.

More information
For advice on cancer screening, visit the American Cancer Society.

New Light Imaging Scan Could Boost Breast Cancer Care

(HealthDay News) -- Medical imaging that uses light waves from a special region of the spectrum called the "terahertz region" may help ensure complete breast cancer tumor removal and eliminate the need for multiple surgeries, a new study finds.

Terahertz light is located between the microwave and infrared portions of the electromagnetic spectrum.

Reporting in the May issue of Radiology, researchers used terahertz imaging to examine breast tissue samples from 22 women who had breast cancer surgery.

"We found that terahertz light could reliably distinguish between normal breast tissue, tumor and even early-stage 'in situ' cancers in excised tissue samples," study lead investigator Vincent P. Wallace said in a prepared statement.

"This technology could aid the surgeon in immediately identifying residual cancer after the main tumor has been removed, thus minimizing the need for additional surgical procedures," Wallace said.

Currently, it can take several days to get test results on excised breast tissue samples. This means that surgeons don't know if the tumor has been completely removed until well after they've done the surgery. Repeat surgeries are often necessary once doctors receive the test results.

Terahertz imaging has the potential to enable surgeons to analyze tissue samples during the initial excision procedure, the researchers concluded.

ClickComments

Balancing Your Hormones Without Drugs... You Can Feel Good Again

Balancing Your Hormones Without Drugs... You Can Feel Good Again

$19.95
[ learn more ]

Add to Cart

Hormone imbalance can be reversed! Look and feel better than ever, just take the time to learn about yourself and read the information contained in this just released e-book about reversing hormone imbalance. Are you ready to finally look and feel great? If so... read on... - E-Book Version.(BH)